Migraine prevention study with atogepant in the UK
Part of Brain & nervous system clinical trials.
This study tests an oral medication called atogepant to prevent migraines in adults in the UK. It aims to see how well it works when prescribed by a general practitioner in primary care.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a doctor-confirmed diagnosis of migraine, either episodic or chronic.
- You have had migraines for at least 1 year, with or without aura.
- You have at least 4 migraine days per month.
- You have not taken atogepant before.
- Your doctor has decided to prescribe atogepant for prevention, and this decision was made before the study was mentioned.
- You are not on other migraine preventive medication, or you have been on a stable preventive medication for at least 3 months.
- You can read and understand English well enough to complete questionnaires, and you have access to a device like a smartphone, tablet, or laptop.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a once-daily pill, atogepant, to see if it safely prevents chronic or episodic migraines in Korean adults. It's meant for people whose doctor has already prescribed the pill for migraine prevention.
This study compares three common migraine prevention medications to see which works best. You might be able to join if you have migraines at least 4 days a month and haven't taken these specific drugs before.
This study tests new ways to monitor how well preventive migraine treatments are working. It is for people with chronic migraine who may be starting or already using preventive medications.
This study tests a medicine called rimegepant to see if it helps prevent migraines. If you have migraine at least 4 days per month, this might be for you.
This study looks at how well the migraine medication ubrogepant works when taken during the early signs of a migraine (prodrome). It may help people who already use ubrogepant for their migraines.
This trial compares two different first-time preventive treatments for migraine in a primary care setting. If you qualify, you'll receive one of the study medications, and the research team will track how well it reduces your migraine days.
Hear when a new Migraine trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.